SCHEMBL4136748

SCHEMBL4136748

COC(=O)C1NCC(NOCc2ccccc2)c2ccsc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 2/20 0.34
CASP1 P29466 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
CPB1 P15086 1/20 0.33
LMNA P02545 1/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CYP2D6 P10635 1/20 0.33
HTR2C P28335 1/20 0.33
MAPK8 P45983 1/20 0.32
MAPK9 P45984 1/20 0.32
MAPK10 P53779 1/20 0.32
ADORA2B P29275 1/20 0.31
MEN1 O00255 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4696597 0.90 NPC1 (0.35) ALDH1A1SMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL5187221 0.84 NPC1 (0.37) TSHRALDH1A1CYP3A4CASP1SMN1; SMN2
SCHEMBL5187915 0.82 ALDH1A1 (0.31) ALDH1A1MEN1KMT2A
SCHEMBL4155681 0.80 ALDH1A1 (0.34) TSHRALDH1A1CYP3A4CASP1SMN1; SMN2
Hydrochloric Acid SCHEMBL4147766 0.79 TSHR (0.34) TSHRALDH1A1CYP3A4CASP1SMN1; SMN2
SCHEMBL4138221 0.78 GPR183 (0.35) TSHRALDH1A1CYP3A4CASP1SMN1; SMN2
SCHEMBL20557971 0.78 CCNB2 (0.35) TSHRALDH1A1CYP3A4CASP1SMN1; SMN2
SCHEMBL20558125 0.76 ACHE (0.34) ALDH1A1NPC1RAB9ACPB1LMNA
SCHEMBL5330841 0.76 TSHR (0.40) TSHRALDH1A1NPC1RAB9AHTR2C
Hydrochloric Acid SCHEMBL4145877 0.74 HTT (0.39) ALDH1A1NPC1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018329-A1 NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS NOVEXEL (FR) 2009-01-15 US disclosed
US-7439253-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors NOVEXEL (FR) 2008-10-21 US disclosed
US-7288549-B2 Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents AVENTIS PHARMA S.A. (FR) 2007-10-30 US disclosed
US-20050245505-A1 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents ENTASIS THERAPEUTICS LIMITED (GB) 2005-11-03 US disclosed
US-20040157826-A1 Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors AVENTIS PHARMA S.A. (FR) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157826-A1 Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors GAA, ALPI, GANAB TSHR 4594/4885ALDH1A1 305/4885CYP3A4 559/4885
US-20050245505-A1 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents FDPS, MRPL21, DHPS TSHR 4641/4885ALDH1A1 1565/4885CYP3A4 957/4885
US-20090018329-A1 NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS GAA, GANAB, ALPI TSHR 4591/4885ALDH1A1 433/4885CYP3A4 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.